FXYD5 and neoplasm: Taken together, our findings suggest that the dysadherin/CA9 axis facilitates CRC cell adaptation to an acidic TME by promoting metabolic reprogramming, activating CAFs, and enabling immune evasion, thereby contributing to enhanced tumor malignancy.